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Abstract
Background: Hereditary cancers account for 5–10% of cancers. In this study BRCA1, BRCA2 and
CHEK2*(1100delC) were analyzed for mutations in 91 HBOC/HBC/HOC families and early onset
breast and early onset ovarian cancer cases.
Methods:  PCR-DHPLC was used for mutation screening followed by DNA sequencing for
identification and confirmation of mutations. Kaplan-Meier survival probabilities were computed
for five-year survival data on Breast and Ovarian cancer cases separately, and differences were
tested using the Log-rank test.
Results: Fifteen (16%) pathogenic mutations (12 in BRCA1 and 3 in BRCA2), of which six were novel
BRCA1 mutations were identified. None of the cases showed CHEK2*1100delC mutation. Many
reported polymorphisms in the exonic and intronic regions of BRCA1 and BRCA2 were also seen.
The mutation status and the polymorphisms were analyzed for association with the clinico-
pathological features like age, stage, grade, histology, disease status, survival (overall and disease
free) and with prognostic molecular markers (ER, PR, c-erbB2 and p53).
Conclusion: The stage of the disease at diagnosis was the only statistically significant (p < 0.0035)
prognostic parameter. The mutation frequency and the polymorphisms were similar to reports on
other ethnic populations. The lack of association between the clinico-pathological variables,
mutation status and the disease status is likely to be due to the small numbers.
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Introduction
Breast cancer is the most common cancer among women
in Chennai with the crude incidence rate (CIR) being
30.1/100,000 in the Madras Metropolitan Tumor Registry
(MMTR). A significant increasing trend in the incidence of
breast cancer was seen during 1982–2005 with an average
annual increase of 0.72 per 100,000 [1]. The trend of ris-
ing incidence rate is likely to continue due to further
changes in life style factors such as age of first child birth
and dietary habits [2].
BRCA1 and BRCA2 genes had been identified by linkage
analysis and positional cloning on large breast cancer
families in the early 1990's [3,4]. This has improved the
understanding of the molecular genetics of the hereditary
breast and ovarian cancer thus providing scope for better
management in these patients and in offering predictive
testing, aggressive screening and preventive strategies to
the unaffected carriers in the same family. The
CHEK2*1100delC mutation confers a low risk of breast
cancer in non-BRCA1/BRCA2 mutation carriers [5]. The
average cumulative risk of breast cancer in a BRCA1 and
BRCA2 mutation carrier is 65% and 45% by the age of 70
years, respectively. For ovarian cancer the risk is 39% and
11%, in BRCA1 and BRCA2 mutation carriers by 70 years,
respectively [6]. Slightly elevated risk of colon and pros-
tate cancer in BRCA1 mutation carriers and increased risk
of other malignancies including pancreatic, stomach and
head and neck cancers and a large increase in the relative
risk for male breast cancer is seen in BRCA2 mutation car-
riers [7,8].
Other genes like TP53, ATM, SKT11, PTEN, PTCH MLH1,
MSH2, PMS1, PMS2, MSH6 have been associated with
increased risk of breast and ovarian cancer as part of other
cancer syndromes [9]. Recently genome wide association
study identified four plausible causative genes namely
FGFR2, TNRC9, MAP3K1 and LSP1 that confer moderate
susceptibility to breast cancer [10].
Generally, hereditary breast cancers are earlier in onset
and have a higher prevalence of bilateral breast cancers.
Breast tumors from BRCA1- carriers are more likely to be
highly proliferative; poorly differentiated (grade III);
more likely to have a medullary or atypical medullary-like
appearance with high degree of lymphocyte infiltration;
and show excess of continuous pushing margins [11].
Moreover these tumors are more often ER, PR and c-erbB2
negative and frequently show p53 alterations [12].
Lakhani and Bell et al report BRCA2  tumors to be of
higher grade than the sporadic group, but this was not
confirmed by Eelora et al, 2005 [13-15]. The BRCA2
tumors are likely to be ER positive [16]. BRCA1 mutation
carriers have an earlier onset of ovarian cancer that is his-
tologically high-grade serous adenocarcinoma [17]. We
had earlier published the data of BRCA1,  BRCA2  and
CHEK2*1100delC mutation status in 22 cases [18]. Here,
we report the clinico-pathological features, BRCA1,
BRCA2 and CHEK2*1100delC mutation status and their
correlation with prognostic markers in 91 cases.
Materials and methods
Materials
Ninety-one eligible cases including the 22 published that
fulfilled the criteria for gene testing were screened for
BRCA1, BRCA2  and CHEK2*1100delC mutations [18].
The criteria were as follows: Early onset of breast cancer
(≤35 years of age) or ovarian cancer (≤40 years of age);
Two cases of breast cancer diagnosed under the age of 50
years in a family (first and second degree relatives); Three
or more cases of breast cancer diagnosed at any age; Pres-
ence of breast and ovarian cancer in the family or in the
same individual; Male breast cancer with a relative (of
either sex) with breast cancer; Family history of Prostate or
pancreatic or colorectal cancer or sarcomas, with breast
cancer in the family. The study includes 65 unilateral, 6
bilateral breast cancer cases, 14 ovarian cancer cases, 3
cases with both breast and ovarian cancer in the same
individual without any family history of cancer, 2 cases
each with family history of breast cancer and soft tissue
sarcoma and 1 case of prostate cancer with family history
of prostate and breast cancer. Of the 91 cases, 54 were
with Family history (including 35 Hereditary Breast Can-
cer families, 15 Hereditary Breast & Ovarian Cancer fami-
lies, 3 Hereditary Ovarian Cancer families and 1 with
family history of Prostate and breast cancer). There were
31 early onset breast cancer (≤ 35 yrs) and 3 early onset
ovarian cancer (≤ 40 yrs) cases without family history of
cancer. Three patients had breast and ovarian cancers,
without a family history. All the patients provided their
informed consent for the study, which was cleared by the
Institutional Ethical committee.
Methods
Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC
The sample collection, DNA isolation, PCR-DHPLC and
sequencing were carried out as previously described [18].
Bioinformatics Analysis
The secondary structure and the tertiary structure of the
normal CHEK2 gene sequence and the two missense vari-
ants were predicted by submitting the sequences to Chou
Fasman secondary structure prediction site and at ExPaSy
server for tertiary structure prediction using Swiss model
[19-22].
Immunohistochemistry
IHC was done for ER, PR, p53 and c-erbB2 expression
studies on available breast cancer cases. IHC was per-
formed as per the standard methodology using primaryHereditary Cancer in Clinical Practice 2009, 7:13 http://www.hccpjournal.com/content/7/1/13
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antibodies; clone ID5 (ER), clone PgR636 (PR), clone
HER2/neu (c-erbB2), and clone DO7 (p53) and second-
ary antibodies; rabbit anti mouse for ER, PR and p53 and
swine anti rabbit for c-erbB2 from Dako [23-26]. The anti-
bodies were used at a dilution of 1:35 for ER and PR
(Dako pharma), 1:350 for HER2/neu (Dako pharma) and
1:200 (Biogenex) or 1:50 (Dako pharma) for p53. Positive
(known positives for each of the markers) and negative
controls (omission of primary antibody) were included in
each run. The scoring was done as described previously
[23-26].
Statistical Analysis
Chi-square test of independence was used for testing the
statistical significance of association between the variables
like age, stage, grade and histological type with disease sta-
tus (i.e. disease free or disease present) and between clin-
ico-pathological features and with each of the prognostic
markers like ER, PR, c-erbB2 and p53 status for the breast
cancer cases. The BRCA1 and BRCA2 mutation status i.e.
mutation positivity or negativity were tested for statistical
association with disease status and prognostic molecular
markers. Yates correction was made wherever indicated.
Fisher's exact probability test was employed to deal with
small frequencies. Kaplan-Meier survival probabilities
were computed for five-year survival data on Breast and
Ovarian cancer cases separately, and differences were
tested using the Log-rank test. All the statistical analyses
were performed using Stata version 10.0 software.
Results
BRCA1 and BRCA2 analysis
Fifteen out of the 91 (16%) samples analyzed had a dele-
terious mutation. Twelve mutations were in BRCA1 and
three in BRCA2 gene. The mutations and genetic variants
were designated according to HUGO recommendations.
The gene, mutation, exon, and the details of age of onset
and family history are given in Table 1. Six of the 15 path-
ogenic mutations were novel and have been submitted to
the GenBank http://www.ncbi.nlm.nih.gov/Genbank.
Apart from the pathogenic mutations, many known mis-
sense variations both in the exonic and the intronic
regions of BRCA1  and  BRCA2  genes were seen in our
study. The common missense variations in the exons and
introns of BRCA1 and BRCA2 gene are given in Table 2.
85/91 (93%) cases showed at least one variation either in
the exon or intron of BRCA1 or BRCA2 gene. Six cases did
not show any variations either in exon or intron of both
BRCA1 and BRCA2 gene. 28/91 (31%) did not show any
variations in BRCA1 and 20/91 (22%) cases did not show
any variations in BRCA2 gene.
CHEK2*1100delC mutation analysis
In our study none of the 91 samples analyzed showed the
CHEK2*1100delC mutation. However, two missense
mutations were seen in three cases. c.1217G>A; p.R406H
which is a known missense mutation was seen in two
patients, both with breast cancer and a family history of
breast cancer. The second missense variation was
c.1175C>T;p.A392V seen in an early onset breast cancer
case without any family history of cancer. The Chou Fas-
man secondary structure prediction showed extension of
β sheet and loss of a turn in the A392V and R406H mis-
sense mutation, respectively when compared with the
normal sequence (Figure 1). The Swiss model for tertiary
structure prediction show marked variation in the struc-
ture of A392V missense change. The R406H missense
mutation, however did not show any change in its tertiary
structure in the Swiss model (Figure 2).
IHC analysis, Clinico-Pathological Features and Statistical 
Analysis
In our study 10/15 BRCA1 mutation positive cases were
breast cancer and 2/16 were ovarian cancer cases. 8/10
BRCA1 mutation positive breast cancer cases were ER and
PR negative and 5/8 were p53 positive. c-erbB2 data was
available for 6 cases, of which 5 were negative and 1 was
positive. Of the three BRCA2 mutation positive cases data
was available for only one case, which was negative for ER,
PR and p53. Clinico-pathological variables like age, stage,
grade, histology, ER, PR, c-erbB2 and p53 status for 65
unilateral, 6 bilateral breast cancers and 14 ovarian can-
cers are given in Table 3. Of the 91 cases, ER, PR, c-erbB2
and p53 data was available only for 59, 57, 50 and 48
cases respectively. Data was not available for 32 cases; 10/
32 patients were being managed outside the Institute and
either declined or were unable to provide paraffin blocks.
In the remaining cases only FNAC was done for the diag-
nosis of the disease, and not enough slides were available
for all the marker study.
Statistical analysis between clinico-pathological variables,
disease status and prognostic markers revealed association
between the stage of the disease at diagnosis and the dis-
ease status, which was statistically significant (p <
0.0035). There is a positive association between earlier
stage at diagnosis and disease free status. No other varia-
bles like grade, age and histological types had significant
association with the disease status and the prognostic
molecular markers. In addition, no significant association
between the mutation status and the clinico-pathological
variables were seen.
The 5 year overall survival (OS) and disease-free survival
(DFS) in breast cancer cases was 75% and 65% and for
ovarian cancer cases was 30% and 22% respectively. The
Plogrank = 0.30 for overall survival and Plogrank = 0.72 for dis-
ease-free survival in breast cancer cases and for ovarian
cancer cases it is Plogrank = 0.42 and Plogrank = 0.89 respec-
tively. The Kaplan-Meier curve for the breast and ovarian
cancer cases are given in Figure 3 and Figure 4.Hereditary Cancer in Clinical Practice 2009, 7:13 http://www.hccpjournal.com/content/7/1/13
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Discussion
In our study on 91 patients, 15 pathogenic mutations
(16%) in BRCA1 and BRCA2 genes were detected. This is
similar to the data from several studies including the study
by Wagner et al who had reported 17% mutation in either
of the BRCA genes [27-31].
There is a four fold greater incidence of BRCA1 mutation
(12) compared to BRCA2 (3) mutations in our series of
South Indian patients. This is different from the North
Indian data wherein almost equal distribution of BRCA1
and BRCA2 mutations was seen in two studies and in the
study by Hedau et al [32,33], 4/24 mutations reported,
Table 1: Gene, exon, mutation description, site of cancer in proband with age of onset and family history
S. No Gene Exon Mutation Site of Cancer Age of onset Family History
1 BRCA1 12 c.4158_4162delCTCTC; 
p.Ser1369SerfsX2
[Acc No. AY144588]*
Breast 28 Mother – B (44 y)
MA – B (50 y)
MGM – B (50 y)
2 BRCA1 13 c.4327C>T; p.R1443X * Breast 40 3 Sisters – B (35 y, 38 y, 48 y)
PA – B (64 y)
3 BRCA1 11C c.1148_1149delAT;
p.Asn383Arg fsX6
[Acc No. AY458144]
Breast 38 2 Sisters (50 and 49 y)
4 BRCA1 14 c.4399C>T; p.Gln1467X
[Acc No. AY06912]
Breast (Metachronous Bil.) and 
uterine
38 (L)
40 (R)
43 (En)
2 sisters – B (39 y)
Mother – O (74 y)
5 BRCA1 16 c.4705_4706insTGGAATC; 
p.Ile1567fsx5
[Acc No. DQ075361]
Breast 45 Mother – O (58 y)
6 BRCA1 17 c.5024_5025insT;
p. Thr1675Thr fsX4
[Acc No. AY706913]
Ovarian 61 Daughter – O (39 y)
7 BRCA1 2 c.68_69delAG; p.Glu23Val fsX16 Breast 33 No family history
8 BRCA1 2 c.68_69delAG; p.Glu23Val fsX16 Breast 33 No family history
9 BRCA1 2 c.68_69delAG; p.Glu23Val fsX16 Breast 39 Mother – O (60 y)
10 BRCA1 2 c.68_69delAG; p.Glu23Val fsX16 Ovarian 59 Sister – O (44 y)
Daughter – B (39 y)
11 BRCA2 11O c.6214_6218delCTTAA; 
p.Ser2072Ser fsX4 *
Breast 38 Mother – B (40 y)
12 BRCA2 1D c.5130_5133delTGTA; 
p.Tyr1693X
Breast 27 No family history
13 BRCA1 2 c.66_67delAG; p. Leu22Leu fsX18 Breast 55 Mother – B (41 y)
O (55 y)
MA – B (47 y)
14 BRCA1 18 c.5118_5120delAAT; p.del1707Ile
[Acc No. FJ940752]
Breast 45 Mother – B (39 y)
MA – B (64 y)
Sister – B (33 y)
15 BRCA2 11G c.2621_2627delAACTGTC;
p. Ile873Ile fsX19
Breast 35 Mother – Cervix (40 y)
MGM – B (60 y)
PA – U (52 y)
B-Breast cancer, O-ovarian cancer, MA-Maternal aunt, PA-Paternal aunt, MGM-Maternal grandmother, Acc No-GenBank accession number, * – 
Mutations already reported in our previous publication [18]Hereditary Cancer in Clinical Practice 2009, 7:13 http://www.hccpjournal.com/content/7/1/13
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were all in BRCA1 gene [34]. The two South Indian studies
have looked at BRCA1 mutations only [35,36].
7/35 HBC families (20%) had mutations in either BRCA1
(5 mutations) or BRCA2 gene (2 mutations). Four of 15,
HBOC cases were found to harbor mutations in BRCA1
gene (30%). Zelada-Hedman et al showed that 35% of the
HBOC families have mutation in BRCA1 gene, but others
report a higher percentage (58% and 43% respectively) of
mutation in BRCA1 gene in HBOC families [28,37,38].
The German consortium (2002) study showed 10% muta-
tion in BRCA2 gene in HBOC families [38]. In our series
we did not find mutation in BRCA2 gene in HBOC fami-
lies, which is similar to the results from a study in the Jap-
anese population [39]. Three of 31 early onset (≤ 35 years)
breast cancer cases had deleterious mutation, 2 in BRCA1
(7%) and 1 in BRCA2 (3%) gene. Peto et al also report
3.5% and 2.4% mutation in BRCA1  and BRCA2  gene,
Table 2: The missense variations in the exons and the introns (defined polymorphisms in BIC database) of BRCA1 and BRCA2 gene and 
their percentage
BRCA1 BRCA2
Polymorphisms Cases (n = 91)
(%)
Polymorphisms Cases (n = 91)
(%)
Exons 3 – c.294A>G; p. L98L * 1 (1%)
11K – c.2311T>C; p. L771L 42 (45.4%) 10B – c.1114C>A; p. H372N 36 (40%)
11N – c.2612C>T; p. P871L 38
(41.2%)
10C – c.1365A>G; p. S455S 1 (1%)
11S – c.3113A>G; p. E1038G 20 (22%) 11B – c.4258G>T; p. D1420Y 2 (2%)
11TU – c.3548A>G; p.K1183R 12 (13%) 11C – c.4779A>C; p. E1593D 3 (3.1%)
16 – c.4956G>A; p. M1652I 4 (4.1%) 11F – c.2538A>C; p. S846S * 2 (2%)
16 – c.4838A>G; p. S1613G 4 (4.1%) 11H – c.2892A>T; p. K964N * 1 (1%)
11P – c.2597G>T; p. R866L * 1 (1%) 11I – c.2971A>G; p. N991D 5 (5.3%)
11K – c.3807T>C; p. V1269V 4 (4.2%)
Introns c.301-41T>C 5 (5.3%)
c.441-34T>C 1 (1%0 c.1-26G>A
c.548-58del T 22 (24%) c.6841+79delTTAA 4 (4.2%)
c.4184-10G>A 1 (1%) c.7807-14T>C 33 (36%)
c.4987-68A>G 22 (24%) c.8755-66T>C 39 (43.2%)
c.4987-92A>G 22 (24%) c.68-21T>G 38 (42%)
c.5075+66G>A 5 (5.3%) c.7804-12T>C 1 (1%)
c.5152+66A>G 2 (2%) 1 (1%)
c.547-64 del T 1 (1%)
Secondary structure as predicted by Chou – Fasman algo- rithm Figure 1
Secondary structure as predicted by Chou – Fasman 
algorithm. a) Normal sequence. b) CHEK2 A392V. c) 
CHEK2 R406H. The missense variations valine and histidine 
are typed in bold and underlined.
A. CHEK2  - Normal Sequence
DCLIKITDFGHSKILGETSLMRTLCGTPTYLAXAAAVSVGTAGYNRAVDCWSLGVILFIC
Helix  ------------>          <----------------> <------------->     <------------------->
Sheet EEEEEEE   EEEEEEEEEEEEEEEEE  EEEEE     EEEEEEEEEEEEE
Turns        T                T
B. CHEK2 – A392V  
DCLIKITDFGHSKILGETSLMRTLCGTPTYLVXAAAVSVGTAGYNRAVDCWSLGVILFIC
Helix  ----------->           <----------------> <------------->     <------------------->
Sheet EEEEEEE   EEEEEEEEEEEEEEEEEEEEEEEEEEE      EEEEEEEEEEEEE
Turns       T                T
C. CHEK2 – R406H
DCLIKITDFGHSKILGETSLMRTLCGTPTYLAXAAAVSVGTAGYNHAVDCWSLGVILFIC
Helix   ------------>          <---------------->            <------------->  <-------------------->
Sheet EEEEEEE   EEEEEEEEEEEEEEEEE  EEEEE     EEEEEEEEEEEEE
Turns   T            
Swiss model predicted protein structures of normal, A392V  and R406H CHEK2 sequences Figure 2
Swiss model predicted protein structures of normal, 
A392V and R406H CHEK2 sequences.Hereditary Cancer in Clinical Practice 2009, 7:13 http://www.hccpjournal.com/content/7/1/13
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respectively in early onset (≤ 35 years) breast cancer cases
[40]. Of the three hereditary ovarian cancer families stud-
ied, one had a deleterious mutation in the BRCA1 gene.
Results published from other Indian groups on BRCA1
&BRCA2 give varying results. Initial studies on smaller
sample size gave higher percentage of mutation detected.
Saxsena et al reported 2.9% (6/204) mutation with largest
sample size so far analyzed [32]. However, this study
includes 34 cases with family history and the rest being
sporadic cases. The table 4 details the published results
from the different groups from India [33-36,41]. The
Table 3: Clinico-pathological characteristics of breast and Ovarian cancer cases
Clinico-pathological features 65 Unilateral breast cases in 
number (%)
6 Bilateral breast cases in 
number (%)
14 Ovarian cases in number 
(%)
Age (years)
35 37 (56.8%) 5 (83.3%) 6 (42.8%)
36–45 17 (26.1%) 1 (16.6%) 3 (21.4%)
46–55 9 (13.8%) - 3 (21.4%)
56–65 1 (1.5%) - -
>65 1 (1.5%) - 2 (14.2%)
Stage
I 8 (12.5%) Lt: 2(33.2%) Rt:1(16.6%) 2 (14.2%)
II 15 (23.0%) Lt: 2(33.2%) Rt: - -
III 37 (56.8%) Lt: – Rt:4(66.6%) 7 (50%)
IV 2 (3.1%) Lt: 2(33.2%) Rt:1(16.6%) 3 (21.4%)
NK 3 (4.6%) - 2 (14.4%)
Grade
I 30 (46.2%) Lt:4(66.6%) Rt:1(16.6%) 3 (21.4%)
II 18 (27.3%) Lt:1(16.6%) Rt:3(50%) 2 (14.2%)
III 10 (15.4%) Lt: – Rt: - 3 (21.4%)
NK 7 (10.1%) Lt:1 (16.6%)Rt:2(33.2%) 6 (42.8%)
Disease Status
Disease free 43 (66.3%) 3 (50%) 5 (35.7%)
Recurrence & disease present 9 (14.0%) 1 (16.6%) 6 (42.8%)
Recurrence & disease free 1 (1.5%) - -
Default 6 (9.1%) 1 (16.6%) 1 (7.1%)
Not treated at CI 6 (9.1%) 1 (16.6%) 2 (14.2%)
Type
IDC 53 (82.1%) Lt:5(83.3%)Rt:5(83.3%) -
Medullary 4 (6.2%) -
Mucinous 1 (1.6%) -
Others 3 (4.6%) Lt:1(16.6%)Rt:1(16.6%)
NK 4 (5.5%) -
ER
Positive 15/55 (27.3%) 0 -
Negative 40/55 (72.7%) 4/4 (100%)
PR
Positive 17/53 (32.0%) 0 -
Negative 36/53 (68.0%) 4/4 (100%)
c-erbB2
Positive 15/46 (32.6%) 1/4(25%) -
Negative 31/46 (67.4%) 3/4 (75%)
P53
Positive 21/44 (47.7%) 1/4(25%) -
Negative 23/44 (52.3%) 3/4 (75%)Hereditary Cancer in Clinical Practice 2009, 7:13 http://www.hccpjournal.com/content/7/1/13
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mutation c.68_69delAG; p.Glu23Val fsX16 was seen in
four cases (two in HBOC families and two in early onset
breast cancer case is the only recurrent mutation seen in
this study. The above mentioned mutation has been iden-
tified as founder mutation in various populations like the
Ashkenazi Jews; however haplotype analysis was not per-
formed in these four families to check for common ances-
tor [28]. These four families are unrelated and are from
different parts of South India, and ethnically different.
Many common missense variants were seen in our series
both in the exon and intron of BRCA1 and BRCA2. Most
have them been previously reported in other populations.
The exonic variants seen in BRCA1 have been reported as
unclassified variants in many studies [39,42,43]. In the
BIC data base, most of the variants have been classified as
having no clinical significance or of unknown clinical sig-
nificance. Case control studies have shown no difference
in the frequencies of these alleles in cases and controls
Kaplan-Meier plot showing Overall survival and Disease free status for Breast cancer cases Figure 3
Kaplan-Meier plot showing Overall survival and Disease free status for Breast cancer cases.
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Kaplan-Meier plot showing Overall survival and Disease free status for Ovarian cancer cases Figure 4
Kaplan-Meier plot showing Overall survival and Disease free status for Ovarian cancer cases.
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[44]. However, we have not analyzed the frequency of the
missense heterozygotes in our control population i.e.
unaffected controls with out any family history of breast
and/or ovarian cancer. The most common exonic mis-
sense variant of BRCA2 gene seen in our cases was N372H.
Studies have shown that N372H appears to confer a small
increased risk for breast cancer [44]. The missense variants
seen in the intronic region of the BRCA1 gene and other
less common exonic and intronic variants in BRCA2 have
also been previously reported in other populations
[28,37,38,40].
The CHEK2*1100delC mutation reported in the western
populations were also screened for in our cases. Though
no CHEK2*1100delC mutation was detected, two mis-
sense mutations in the CHEK2  gene (p.R406H and
p.A392V) were seen in three cases. The residues, arginine
and alanine at positions 406 and 392 are conserved across
species. Additionally, the secondary structure prediction
using the Chou-Fasman algorithm predicts changes in the
secondary structure for both the missense variations [19].
The Swiss Model software too shows a marked change in
the structure for the A392V missense variation, though the
R406H did not show a visible change. The variation
(R406H) was not seen to be associated with breast cancer
cases in French Canadian women [45]. The pathogenicity
of the variations can however be confirmed by segregation
analysis in other affected family members or other func-
tional studies or screening the normal controls. Two out
of the three cases had a family history of breast cancer but
we could not get the sample from the other affected family
member for testing. The patient with the A392V mutation
was an early onset breast cancer patient without any fam-
ily history. Rest of the coding region of the CHEK2 gene
was not screened for mutations.
In our series, nearly 80% of the breast cancer patients were
≤ 45 years of age at diagnosis, with 52.7% being ≤ 35 years
at diagnosis, as in other studies [46]. Majority of the breast
cancer cases were high-grade tumors (56%). Ho et al
reported that 25%–37% of hereditary breast cancers not
associated with BRCA1 mutations were ER negative but
we found 68% to be negative for ER expression in our
study [42]. This correlates well with our hospital statistics
in sporadic cancers, wherein 62% of the pre-menopausal
patients harbor tumours, which are ER negative.
Our study looked at the association between clinico-path-
ological features, disease status, and prognostic markers.
We also looked at the association between the mutation
status with disease status and prognostic markers. The
stage of the disease at diagnosis and the disease status
alone emerged to be statistically significant, wherein a
positive association between earlier stage at diagnosis and
disease free status was observed. None of the other param-
eters showed any association. Disease free and overall sur-
vival of BRCA mutation positive breast or ovarian cancers
did not significantly differ from the BRCA mutation nega-
tive cases. Other groups have also not found any survival
difference between BRCA mutation positive versus nega-
tive cases [46-49].
Of the 91 cases analyzed, 13 (14%) of the affected
probands were issues of consanguineous marriage and
had either ovarian cancers (3) or breast cancers (10).
Table 4: Published results from various Indian groups on BRCA1 and BRCA2 mutation status on hereditary breast and ovarian cancer 
families or early onset breast cancer cases
Total No. cases Gene(s) Mutation detected Authors and Year
14 cases with F/H of BC & OC BRCA1 3/14 (21%) Kumar et al (2002)
20 cases with F/H of B & OC or early onset
(< 35 y)
BRCA1 &BRCA2 2/20 (10%) (BRCA1) Saxsena et al 2002
24 cases with F/H of breast cancer and 100 sporadic 
cases
BRCA1 &BRCA2 6/24 (25%) (BRCA1) Hedau el at 2004
16 cases F/H of BC & OC and 20 sporadic cases BRCA1 &BRCA2 5/16 (31%) (BRCA1 &BRCA2) Valarmathi et al 2004
23 cases with F/H of BC & OC BRCA1 1/23 Gajalakshmi et al 2006
204 cases, 34 with F/H, 105 early onset (<40 y) and 65 
late onset
BRCA1 &BRCA2 6/204 (2.9) (BRCA1 &BRCA2)
except for one mutation were seen either in 
early onset cases or with F/H
Saxena et al 2006
91 cases, 54 with F/H of BC & OC, 34 early onset (≤ 35 
y for BC and ≤ 40 y for OC); 3 HBOC in same individual
BRCA1 &BRCA2 15/91 (16%) (BRCA1 &BRCA2) Current studyHereditary Cancer in Clinical Practice 2009, 7:13 http://www.hccpjournal.com/content/7/1/13
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Though susceptibility to breast cancer is inhereited as an
autosomal dominant trait, modifier genes when present
in homozygous state might further increase the risk of
cancer.
Conclusion
We have looked at the prevalence of BRCA1, BRCA2 and
CHEK1100delC mutation in breast and ovarain caner
patients in India. The prevalence of BRCA1 and BRCA2
gene mutaion is similar to other population.
CHEK1100delC mutation was not seen our study series.
Asoociation between the clinico-pathological variables
and mutation status with disease status and prognostic
markers revealed significant assocaition between the stage
at diagnosis and disease free status alone.
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